Korean Drug Co., Ltd. - Laporan Laba Rugi (TTM)

Korean Drug Co., Ltd.
KR ˙ KOSDAQ
₩ 4,580.00 ↑10.00 (0.22%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Korean Drug Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 64,992 66,789 69,292 68,689 70,083 74,466 76,360 79,302 82,376 79,984 81,140 83,004 82,179 81,375 80,541 77,923 74,410 73,001 66,774 62,744
Change (%) 2.77 3.75 -0.87 2.03 6.25 2.54 3.85 3.88 -2.90 1.45 2.30 -0.99 -0.98 -1.02 -3.25 -4.51 -1.89 -8.53 -6.04
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 37,205 38,100 39,008 38,211 40,855 43,400 45,365 47,171 47,351 45,467 45,703 45,363 44,923 44,025 43,592 40,579 38,017 38,600 35,355 34,971
Change (%) 2.41 2.38 -2.04 6.92 6.23 4.53 3.98 0.38 -3.98 0.52 -0.74 -0.97 -2.00 -0.98 -6.91 -6.31 1.53 -8.41 -1.09
% of Revenue 57.24 57.04 56.30 55.63 58.29 58.28 59.41 59.48 57.48 56.84 56.33 54.65 54.66 54.10 54.12 52.08 51.09 52.88 52.95 55.74
Gross Operating Profit 27,787 28,689 30,284 30,478 29,229 31,065 30,995 32,131 35,025 34,517 35,438 37,641 37,256 37,350 36,949 37,343 36,393 34,401 31,420 27,774
Change (%) 3.25 5.56 0.64 -4.10 6.28 -0.23 3.67 9.00 -1.45 2.67 6.22 -1.02 0.25 -1.07 1.07 -2.55 -5.47 -8.67 -11.60
% of Revenue 42.76 42.96 43.70 44.37 41.71 41.72 40.59 40.52 42.52 43.16 43.67 45.35 45.34 45.90 45.88 47.92 48.91 47.12 47.05 44.26
SG&A 16,609 16,530 17,008 18,584 18,318 18,529 18,131 17,917 18,238 19,111 19,590 19,560 19,460 29,441 29,153 34,455 34,954 29,171 29,251 23,454
Change (%) -0.48 2.89 9.26 -1.43 1.15 -2.15 -1.18 1.79 4.79 2.51 -0.15 -0.51 51.29 -0.98 18.19 1.45 -16.55 0.28 -19.82
% of Revenue 25.56 24.75 24.55 27.05 26.14 24.88 23.74 22.59 22.14 23.89 24.14 23.57 23.68 36.18 36.20 44.22 46.97 39.96 43.81 37.38
R&D
Change (%)
% of Revenue
OpEx 54,839 55,750 57,157 58,008 60,442 63,200 64,698 66,244 66,734 65,655 66,355 65,994 65,497 74,655 73,947 76,251 74,162 68,897 65,641 59,337
Change (%) 1.66 2.52 1.49 4.20 4.56 2.37 2.39 0.74 -1.62 1.07 -0.54 -0.75 13.98 -0.95 3.12 -2.74 -7.10 -4.72 -9.60
% of Revenue 84.38 83.47 82.49 84.45 86.24 84.87 84.73 83.53 81.01 82.09 81.78 79.51 79.70 91.74 91.81 97.85 99.67 94.38 98.30 94.57
Operating Income 10,152 11,039 12,134 10,681 9,642 11,266 11,662 13,058 15,642 14,329 14,785 17,010 16,682 6,720 6,594 1,672 247 4,105 1,133 3,407
Change (%) 8.74 9.92 -11.98 -9.73 16.85 3.51 11.97 19.79 -8.39 3.19 15.04 -1.93 -59.72 -1.87 -74.65 -85.22 1,560.64 -72.40 200.71
% of Revenue 15.62 16.53 17.51 15.55 13.76 15.13 15.27 16.47 18.99 17.91 18.22 20.49 20.30 8.26 8.19 2.15 0.33 5.62 1.70 5.43
Interest Expense -6 -3 -3 -2 -1 -2 -1 -2 -2 -2 -2 -2 -2 -3 -3 -4 -4 -4 -4 -4
Change (%) -44.05 -19.24 -24.02 -27.45 9.69 -6.87 15.04 14.66 11.72 5.58 0.81 3.27 30.89 13.32 19.04 -13.49 20.42 5.17 -10.76
% of Revenue -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.01 -0.00 -0.01 -0.01 -0.01
Net Income 9,240 7,360 9,261 7,266 7,392 9,042 9,443 9,828 12,055 11,809 12,657 5,450 3,561 -4,917 -5,315 -1,242 -390 2,995 447 3,549
Change (%) -20.35 25.84 -21.55 1.74 22.32 4.43 4.08 22.65 -2.04 7.18 -56.94 -34.66 -238.08 8.11 -76.63 -68.64 -868.79 -85.06 693.41
% of Revenue 14.22 11.02 13.37 10.58 10.55 12.14 12.37 12.39 14.63 14.76 15.60 6.57 4.33 -6.04 -6.60 -1.59 -0.52 4.10 0.67 5.66

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista